Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Flat Capital AB (publ) in connection with its listing on Nasdaq First North Growth Market
Mandate

Vinge has advised Flat Capital AB (publ) in connection with its listing on Nasdaq First North Growth Market

October 20, 2021 Capital Markets and Public M&A

Vinge has advised Flat Capital AB (publ) (“Flat Capital” or the “Company”) in connection with its listing on Nasdaq First North Growth Market. The prospectus was published on 29 September 2021 and the first day of trading on Nasdaq First North Growth Market was 20 October 2021.

Flat Capital is an investment company founded by Nina and Sebastian Siemiatkowski that focuses on companies with prominent entrepreneurs in leading positions. The company aims to contribute long-term capital to entrepreneur-led companies that may otherwise be dependent on investors with shorter time horizons. The largest investments are Klarna Holding AB, Budbee AB and True Software Scandinavia AB (Truecaller).


Vinge’s team consisted of Jesper Schönbeck, Joel Wahlberg, Anna Grigorian and Anna Svensson.

 

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026